erlotinib hydrochloride has been researched along with exel-7647 in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (exel-7647) | Trials (exel-7647) | Recent Studies (post-2010) (exel-7647) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 13 | 3 | 12 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | exel-7647 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0252 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.05 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.05 | |
| Ephrin type-A receptor 2 | Homo sapiens (human) | 0.05 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.05 | |
| Ephrin type-B receptor 4 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aftab, DT; Bentzien, F; Cancilla, B; Chen, J; Chu, F; De Costa, A; Engell, K; Gendreau, SB; Jackman, L; Jaeger, CT; Joly, AH; Keast, P; Laird, AD; Lutman, J; Martini, JF; Meyer, SM; Shi, Y; Ventura, R; Wang, J; Yakes, FM; Yu, P; Zhang, W | 1 |
| Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH | 1 |
| Aftab, D; Chen, X; Chmielecki, J; Hutchinson, K; Kris, MG; Miller, V; Pao, W; Pietanza, MC; Rizvi, N; Shen, R; Stout, T; Viale, A; Zhao, Z | 1 |
1 trial(s) available for erlotinib hydrochloride and exel-7647
| Article | Year |
|---|---|
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2012 |
2 other study(ies) available for erlotinib hydrochloride and exel-7647
| Article | Year |
|---|---|
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Mice, SCID; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2007 |
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azabicyclo Compounds; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2012 |